Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine vs sufentanil for postoperative nausea and vomiting after radical mastectomy
ChiCTR2400089317Phase 4Not yet recruiting
- Sponsor
- Department of Anesthesiology, Changhai Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine in breast cancer, postoperative pain and postoperative nausea and vomiting (PONV) (2 arms), sponsored by Department of Anesthesiology, Changhai Hospital. Primary endpoint: Incidence of postoperative nausea and vomiting within 48 hours. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
oliceridine
03
Conditions
breast cancerpostoperative painpostoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2400089317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089317.